VCCRI: Update on historic pregnancy breakthrough

Australia’s first clinical trial to potentially identify pregnant women at risk of recurrent miscarriages or having a baby with birth defects is currently underway, with Victor Chang Cardiac Research Institute’s Professor Sally Dunwoodie leading the study. The landmark clinical trial builds on Professor Dunwoodie’s historic breakthrough which discovered that a deficiency in a vital molecule, known as NAD, can cause birth defects and miscarriage in families. To learn more about the study, read the article here. 


Disclaimer: This material has been prepared by Victor Chang Cardiac Research Institute, published on 10 August 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More